

# Ding-Wei Ye

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5116182/publications.pdf>

Version: 2024-02-01

187  
papers

4,107  
citations

147566

31  
h-index

189595

50  
g-index

192  
all docs

192  
docs citations

192  
times ranked

6397  
citing authors

#	ARTICLE	IF	CITATIONS
1	Special issue “The advance of solid tumor research in China” Multi-omics analysis based on 1311 clear cell renal cell carcinoma samples identifies a glycolysis signature associated with prognosis and treatment response. <i>International Journal of Cancer</i> , 2023, 152, 66-78.	2.3	4
2	Inherited Mutations in Chinese Men With Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 54-62.	2.3	13
3	Presence of CD133-positive circulating tumor cells predicts worse progression-free survival in patients with metastatic castration-sensitive prostate cancer. <i>International Journal of Urology</i> , 2022, 29, 383-389.	0.5	6
4	Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1923-1935.	2.0	19
5	IL-1A is associated with postoperative survival and immune contexture in clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	3
6	Managing advanced prostate cancer in the Asia Pacific region: “Real-world” application of Advanced Prostate Cancer Consensus Conference 2019 statements. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 686-695.	0.7	5
7	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 6-11.	0.9	4
8	Re: Fabio Turco, Andrew Armstrong, Gerhardt Attard, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2022.02.010">https://doi.org/10.1016/j.eururo.2022.02.010</a> . <i>European Urology</i> , 2022, , .	0.9	0
9	Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial. <i>BMC Medicine</i> , 2022, 20, 84.	2.3	11
10	Stereotactic Radiotherapy for Lesions Detected via 68Ga-Prostate-specific Membrane Antigen and 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Nonmetastatic Prostate Cancer with Early Prostate-specific Antigen Progression on Androgen Deprivation Therapy: A Prospective Single-center Study. <i>European Urology Oncology</i> , 2022, 5, 420-427.	2.6	12
11	A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population. <i>Nature Communications</i> , 2022, 13, 2052.	5.8	48
12	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	0.9	51
13	Identification of a methylation panel aid in risk stratification in node-positive penile squamous cell carcinoma. <i>International Journal of Cancer</i> , 2021, 148, 1289-1298.	2.3	1
14	Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. <i>Cancer Science</i> , 2021, 112, 305-313.	1.7	62
15	A 5-lncRNA Signature Associated with Smoking Predicts the Overall Survival of Patients with Muscle-Invasive Bladder Cancer. <i>Disease Markers</i> , 2021, 2021, 1-10.	0.6	3
16	Multi-omics reveals novel prognostic implication of SRC protein expression in bladder cancer and its correlation with immunotherapy response. <i>Annals of Medicine</i> , 2021, 53, 596-610.	1.5	13
17	Identification of low-frequency variants of UGT1A3 associated with bladder cancer risk by next-generation sequencing. <i>Oncogene</i> , 2021, 40, 2382-2394.	2.6	8
18	Epidemiology and genomics of prostate cancer in Asian men. <i>Nature Reviews Urology</i> , 2021, 18, 282-301.	1.9	111

#	ARTICLE	IF	CITATIONS
19	Pazopanib together with 6â€“8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 2078-2083.	0.6	3
20	ATM-phosphorylated SPOP contributes to 53BP1 exclusion from chromatin during DNA replication. <i>Science Advances</i> , 2021, 7, .	4.7	22
21	m6A Regulator-Mediated Methylation Modification Model Predicts Prognosis, Tumor Microenvironment Characterizations and Response to Immunotherapies of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 709579.	1.3	10
22	Genetic polymorphisms at 19q13.33 are associated with [âˆ2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer. <i>Prostate</i> , 2021, 81, 971-982.	1.2	4
23	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	48
24	Combination of body mass index and albumin predicts the survival in metastatic castrationâ€resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials. <i>Cancer Medicine</i> , 2021, 10, 6697-6704.	1.3	7
25	SPOP mutation induces replication over-firing by impairing Geminin ubiquitination and triggers replication catastrophe upon ATR inhibition. <i>Nature Communications</i> , 2021, 12, 5779.	5.8	14
26	UriBLAD. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 61-70.	1.2	3
27	Adenylate cyclaseâ€activating polypeptide 1 gene methylation predicts prognosis and the immune microenvironment of bladder cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e597.	1.7	1
28	Systematic Genome-Wide Profiles Reveal Alternative Splicing Landscape and Implications of Splicing Regulator DExD-Box Helicase 21 in Aggressive Progression of Adrenocortical Carcinoma. <i>Phenomics</i> , 2021, 1, 243-256.	0.9	13
29	Comprehensive Multi-Omics Identification of Interferon-Î³ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 734646.	2.2	13
30	LncRNA RP11-89 facilitates tumorigenesis and ferroptosis resistance through PROM2-activated iron export by sponging miR-129-5p in bladder cancer. <i>Cell Death and Disease</i> , 2021, 12, 1043.	2.7	89
31	A Germline Variant at 8q24 Contributes to the Serum p2PSA Level in a Chinese Prostate Biopsy Cohort. <i>Frontiers in Oncology</i> , 2021, 11, 753920.	1.3	2
32	ACSL4 Expression Is Associated With CD8+ T Cell Infiltration and Immune Response in Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 754845.	1.3	8
33	Prognostic Immunophenotyping Clusters of Clear Cell Renal Cell Carcinoma Defined by the Unique Tumor Immune Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 785410.	1.8	12
34	Protumorigenic Role of Elevated Levels of DNA Polymerase Epsilon Predicts an Immune-Suppressive Microenvironment in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 751977.	1.1	6
35	Integrative 5-Methylcytosine Modification Immunologically Reprograms Tumor Microenvironment Characterizations and Phenotypes of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 772436.	1.8	8
36	Comparison of different lymph node staging schemes in prostate cancer patients with lymph node metastasis. <i>International Urology and Nephrology</i> , 2020, 52, 87-95.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Obesity is a predictor in prostate cancer patients receiving prostatectomy after neoadjuvant hormonal therapy. <i>Tumori</i> , 2020, 106, 133-138.	0.6	3
38	Prostate Cancer and Prostatic Diseases Best of Asia, 2019: challenges and opportunities. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 197-198.	2.0	12
39	Androgen receptor reverses the oncometabolite R-2-hydroxyglutarate-induced prostate cancer cell invasion via suppressing the circRNA-51217/miRNA-646/TGF $\beta$ 1/p-Smad2/3 signaling. <i>Cancer Letters</i> , 2020, 472, 151-164.	3.2	43
40	Importance of HPV in Chinese Penile Cancer: A Contemporary Multicenter Study. <i>Frontiers in Oncology</i> , 2020, 10, 1521.	1.3	9
41	Identification of tumor-infiltrating immune cells and prognostic validation of tumor-infiltrating mast cells in adrenocortical carcinoma: results from bioinformatics and real-world data. <i>Oncolmmunology</i> , 2020, 9, 1784529.	2.1	27
42	Survival after radical cystectomy for bladder cancer: Multicenter comparison between minimally invasive and open approaches. <i>Asian Journal of Urology</i> , 2020, 7, 291-300.	0.5	2
43	LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression. <i>Cell Death and Disease</i> , 2020, 11, 638.	2.7	26
44	Prognostic Value of Local Treatment in Prostate Cancer Patients With Different Metastatic Sites: A Population Based Retrospective Study. <i>Frontiers in Oncology</i> , 2020, 10, 527952.	1.3	6
45	Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. <i>Frontiers in Oncology</i> , 2020, 10, 664.	1.3	19
46	A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration. <i>Clinical Cancer Research</i> , 2020, 26, 4551-4558.	3.2	49
47	Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. , 2020, 8, e000437.		86
48	Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies. <i>BMC Cancer</i> , 2020, 20, 219.	1.1	12
49	Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer. <i>Oncologist</i> , 2020, 25, e1042-e1050.	1.9	17
50	Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 3278-3286.	1.3	3
51	<p>Metabolically Abnormal Obesity Increases the Risk of Advanced Prostate Cancer in Chinese Patients Undergoing Radical Prostatectomy</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 1779-1787.	0.9	5
52	The Rare Variant rs35356162 in UHRF1BP1 Increases Bladder Cancer Risk in Han Chinese Population. <i>Frontiers in Oncology</i> , 2020, 10, 134.	1.3	16
53	A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer. <i>Oncolmmunology</i> , 2020, 9, 1762473.	2.1	33
54	Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer. <i>Prostate</i> , 2020, 80, 950-961.	1.2	31

#	ARTICLE	IF	CITATIONS
55	Development and validation of a mitochondrial metabolism-associated nomogram for prediction of prognosis in clear cell renal cell carcinoma. <i>Clinical and Translational Medicine</i> , 2020, 10, e120.	1.7	3
56	Surgical Volume, Safety, Drug Administration, and Clinical Trials During COVID-19: Single-center Experience in Shanghai, China. <i>European Urology</i> , 2020, 78, 120-122.	0.9	11
57	<p>&lt;p>Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)&lt;/p>&lt;/p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 2127-2140.	0.9	12
58	Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation. <i>Cancers</i> , 2020, 12, 831.	1.7	11
59	Fatty Acid Synthase Correlates With Prognosis-Related Abdominal Adipose Distribution and Metabolic Disorders of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 610229.	1.6	18
60	GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers. <i>Cancer Letters</i> , 2020, 485, 45-55.	3.2	42
61	Prognosis of the 8th TNM Staging System for Penile Cancer and Refinement of Prognostication by Incorporating High Risk Human Papillomavirus Status. <i>Journal of Urology</i> , 2020, 203, 562-569.	0.2	24
62	Tislelizumab plus cisplatin/carboplatin and gemcitabine versus placebo plus cisplatin/carboplatin and gemcitabine in Chinese patients with advanced urothelial carcinoma: A phase III trial in progress.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS588-TPS588.	0.8	0
63	Application of fluorescence in situ hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population. <i>Asian Journal of Urology</i> , 2019, 6, 114-121.	0.5	8
64	Causes of Death and Conditional Survival of Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 591.	1.3	20
65	Development and validation of lncRNAs-based nomogram for prediction of biochemical recurrence in prostate cancer by bioinformatics analysis. <i>Journal of Cancer</i> , 2019, 10, 2927-2934.	1.2	16
66	The novel BET/CP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. <i>EMBO Molecular Medicine</i> , 2019, 11, e10659.	3.3	56
67	Family history is significantly associated with prostate cancer and its early onset in Chinese population. <i>Prostate</i> , 2019, 79, 1762-1766.	1.2	6
68	Adverse Effect of Lymph Node Dissection in Metastatic Renal Cell Cancer Patients Treated with Cytoreductive Nephrectomy: A Contemporary Analysis of Survival. <i>Journal of Cancer</i> , 2019, 10, 4639-4646.	1.2	0
69	Development and External Validation of a Novel 12-Gene Signature for Prediction of Overall Survival in Muscle-Invasive Bladder Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 856.	1.3	16
70	Log Odds Could Better Predict Survival in Muscle-Invasive Bladder Cancer Patients Compared with pN and Lymph Node Ratio. <i>Journal of Cancer</i> , 2019, 10, 249-256.	1.2	20
71	Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients. <i>European Urology</i> , 2019, 76, 280-283.	0.9	41
72	Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 89-99.	0.7	8

#	ARTICLE	IF	CITATIONS
73	circLPAR1 is a novel biomarker of prognosis for muscle-invasive bladder cancer with invasion and metastasis by miR-762. <i>Oncology Letters</i> , 2019, 17, 3537-3547.	0.8	34
74	Construction and Validation of a 9-Gene Signature for Predicting Prognosis in Stage III Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 152.	1.3	19
75	Human epidermal growth factor receptor 2 amplification as a biomarker for treatment in patients with lymph node-metastatic penoscrotal extramammary Paget's disease. <i>Oncology Letters</i> , 2019, 17, 2677-2686.	0.8	6
76	Retinoic Acid-Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer. <i>Cancer Research</i> , 2019, 79, 2604-2618.	0.4	87
77	Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial. <i>Oncologist</i> , 2019, 24, e702-e708.	1.9	70
78	Incorporating non-biological factors into the TNM staging system for better prognostication and decision-making in testicular cancer. <i>World Journal of Urology</i> , 2019, 37, 2165-2173.	1.2	5
79	AMPK Promotes SPOP-Mediated NANOG Degradation to Regulate Prostate Cancer Cell Stemness. <i>Developmental Cell</i> , 2019, 48, 345-360.e7.	3.1	66
80	Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes. <i>European Urology Focus</i> , 2019, 5, 737-741.	1.6	25
81	Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early-onset disease. <i>Cancer</i> , 2019, 125, 1060-1069.	2.0	28
82	Prognosis of Patients With Testicular Carcinoma Is Dependent on Metastatic Site. <i>Frontiers in Oncology</i> , 2019, 9, 1495.	1.3	14
83	Adjuvant axitinib dose modification in renal cell carcinoma (RCC): Analysis of the ATLAS study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4573-4573.	0.8	2
84	Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 141-141.	0.8	7
85	Elevated CD36 expression correlates with increased visceral adipose tissue and predicts poor prognosis in ccRCC patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 571-571.	0.8	1
86	Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab. <i>Medical Science Monitor</i> , 2019, 25, 6518-6522.	0.5	4
87	Conditional disease-free survival in high-risk renal cell carcinoma treated with sunitinib. <i>Aging</i> , 2019, 11, 11490-11503.	1.4	2
88	Adjuvant hormone therapy after radical prostatectomy in high-risk localized and locally advanced prostate cancer: First multicenter, observational study in China. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 511-520.	0.7	7
89	Is cytoreductive nephrectomy necessary in metastatic renal cell carcinoma with primary kidney tumor in situ treated by sunitinib: Real-world data from a single Chinese center.. <i>Journal of Clinical Oncology</i> , 2019, 37, 570-570.	0.8	0
90	Germline DNA damage repair gene alterations in Chinese prostate patients: More than HRR and MMR.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13041-e13041.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Identification and Validation of Stromal Immunity Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3069-3078.	3.2	124
92	Downregulation of long non-coding RNA ENSG00000241684 is associated with poor prognosis in advanced clear cell renal cell carcinoma. <i>European Journal of Surgical Oncology</i> , 2018, 44, 840-846.	0.5	10
93	Identification and validation of an 18-gene signature highly-predictive of bladder cancer metastasis. <i>Scientific Reports</i> , 2018, 8, 374.	1.6	10
94	SOX2 and SOX12 are predictive of prognosis in patients with clear cell renal cell carcinoma. <i>Oncology Letters</i> , 2018, 15, 4564-4570.	0.8	22
95	Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. <i>European Urology</i> , 2018, 73, 322-339.	0.9	130
96	Measurement of Metastasis in the Follow-Up of Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 514-514.	0.8	2
97	Comprehensive Analysis of <i>BAP1</i> Somatic Mutation in Clear Cell Renal Cell Carcinoma to Explore Potential Mechanisms <i>in Silico</i> . <i>Journal of Cancer</i> , 2018, 9, 4108-4116.	1.2	17
98	High expression of F2RL3 correlates with aggressive features and poor survival in clear cell renal cell carcinoma. <i>Journal of Cancer</i> , 2018, 9, 3400-3406.	1.2	1
99	Modification of American Joint Committee on cancer prognostic groups for renal cell carcinoma. <i>Cancer Medicine</i> , 2018, 7, 5431-5438.	1.3	21
100	Validation of Urine-based Gene Classifiers for Detecting Bladder Cancer in a Chinese Study. <i>Journal of Cancer</i> , 2018, 9, 3208-3215.	1.2	0
101	Forkhead box series expression network is associated with outcome of clear cell renal cell carcinoma. <i>Oncology Letters</i> , 2018, 15, 8669-8680.	0.8	16
102	Genome-wide Association Study (GWAS) of Germline Copy Number Variations (CNVs) Reveal Genetic Risks of Prostate Cancer in Chinese population. <i>Journal of Cancer</i> , 2018, 9, 923-928.	1.2	13
103	PC3 rs544190G>A and prostate cancer risk in an eastern Chinese population. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2018, 44, 500-505.	0.7	3
104	SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 145.	3.5	43
105	Prognostic value of Lactate dehydrogenase in patients with clear cell renal cell carcinoma. <i>Oncology Letters</i> , 2018, 16, 866-874.	0.8	26
106	Impact of Estrogen on the Relationship Between Obesity and Renal Cell Carcinoma Risk in Women. <i>EBioMedicine</i> , 2018, 34, 108-112.	2.7	11
107	B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients. <i>BMC Cancer</i> , 2018, 18, 590.	1.1	15
108	Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy. <i>Prostate</i> , 2018, 78, 1215-1221.	1.2	9



#	ARTICLE	IF	CITATIONS
109	Vorolanib (CM082), everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 2/3, double-blind, multi-center trial.. Journal of Clinical Oncology, 2018, 36, TPS4605-TPS4605.	0.8	0
110	Efficacy and safety of pazopanib (PAZ) versus sunitinib (SUN) in patients (pts) with locally advanced or metastatic renal cell carcinoma (RCC): A pooled China subgroup analysis from COMPARZ studies.. Journal of Clinical Oncology, 2018, 36, e16588-e16588.	0.8	1
111	Prevalence of residual tumor in the prostate after contemporary systemic therapy.. Journal of Clinical Oncology, 2018, 36, e17001-e17001.	0.8	0
112	Tumor Infiltrating Mast Cells (TIMs) Confers a Marked Survival Advantage in Nonmetastatic Clear-Cell Renal Cell Carcinoma. Annals of Surgical Oncology, 2017, 24, 1435-1442.	0.7	33
113	PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness. Scientific Reports, 2017, 7, 2074.	1.6	21
114	A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia. Asian Journal of Urology, 2017, 4, 75-85.	0.5	23
115	Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients. Scientific Reports, 2017, 7, 7587.	1.6	15
116	Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status. Scientific Reports, 2017, 7, 8869.	1.6	40
117	<i>TEX15</i> : A DNA repair gene associated with prostate cancer risk in Han Chinese. Prostate, 2017, 77, 1271-1278.	1.2	9
118	High CXC chemokine receptor 1 level represents an independent negative prognosticator in non-metastatic clear-cell renal cell carcinoma patients. Oncolmmunology, 2017, 6, e1359450.	2.1	6
119	Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 605.e17-605.e23.	0.8	39
120	Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: Results from a Multicenter Study in China. Prostate, 2017, 77, 1221-1229.	1.3	26
121	Identification and validation of an eight-gene expression signature for predicting high Fuhrman grade renal cell carcinoma. International Journal of Cancer, 2017, 140, 1199-1208.	2.3	29
122	Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World Journal of Urology, 2017, 35, 379-387.	1.2	260
123	NUDT expression is predictive of prognosis in patients with clear cell renal cell carcinoma. Oncology Letters, 2017, 14, 6121-6128.	0.8	10
124	Validation of the novel susceptibility loci for prostate cancer in a Chinese population. Oncology Letters, 2017, 15, 2567-2573.	0.8	3
125	Beyond chemotherapy for advanced disease—the role of EGFR and PD-1 inhibitors. Translational Andrology and Urology, 2017, 6, 848-854.	0.6	12
126	The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma. Scientific Reports, 2017, 7, 9846.	1.6	25



#	ARTICLE	IF	CITATIONS
127	NR1H3 Expression is a Prognostic Factor of Overall Survival for Patients with Muscle-Invasive Bladder Cancer. <i>Journal of Cancer</i> , 2017, 8, 852-860.	1.2	13
128	Expression of ARID1B Is Associated With Poor Outcomes and Predicts the Benefit from Adjuvant Chemotherapy in Bladder Urothelial Carcinoma. <i>Journal of Cancer</i> , 2017, 8, 3490-3497.	1.2	13
129	PBRM1 regulates proliferation and the cell cycle in renal cell carcinoma through a chemokine/chemokine receptor interaction pathway. <i>PLoS ONE</i> , 2017, 12, e0180862.	1.1	12
130	Decreased TCL6 expression is associated with poor prognosis in patients with clear cell renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 5789-5799.	0.8	43
131	High NUCB2 expression level represents an independent negative prognostic factor in Chinese cohorts of non-metastatic clear cell renal cell carcinoma patients. <i>Oncotarget</i> , 2017, 8, 35244-35254.	0.8	11
132	Polymorphisms in nucleotide excision repair genes and risk of primary prostate cancer in Chinese Han populations. <i>Oncotarget</i> , 2017, 8, 24362-24371.	0.8	21
133	Renal cell carcinoma histological subtype distribution differs by age, gender, and tumor size in coastal Chinese patients. <i>Oncotarget</i> , 2017, 8, 71797-71804.	0.8	25
134	An oral methionine aminopeptidase II inhibitor for high-risk non-muscle invasive bladder cancer relapsed after intravesical therapies: Update of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 303-303.	0.8	2
135	Genetic variants in insulin-like growth factor binding protein-3 are associated with prostate cancer susceptibility in Eastern Chinese Han men. <i>OncoTargets and Therapy</i> , 2016, 9, 61.	1.0	8
136	Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib. <i>Oncotarget</i> , 2016, 7, 26879-26887.	0.8	12
137	Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases. <i>Asian Journal of Andrology</i> , 2016, 18, 525.	0.8	11
138	Serum Adiponectin Level May be an Independent Predictor of Clear Cell Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2016, 7, 1340-1346.	1.2	18
139	Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study. <i>International Journal of Urology</i> , 2016, 23, 404-411.	0.5	26
140	Prognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib. <i>Future Oncology</i> , 2016, 12, 1783-1793.	1.1	0
141	Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma. <i>Scientific Reports</i> , 2016, 6, 23594.	1.6	27
142	Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese population. <i>Scientific Reports</i> , 2016, 6, 21677.	1.6	26
143	Genome-Wide Association Study of Bladder Cancer in a Chinese Cohort Reveals a New Susceptibility Locus at 5q12.3. <i>Cancer Research</i> , 2016, 76, 3277-3284.	0.4	46
144	Long non-coding RNA LOC572558 inhibits bladder cancer cell proliferation and tumor growth by regulating the AKT-MDM2-p53 signaling axis. <i>Cancer Letters</i> , 2016, 380, 369-374.	3.2	60

#	ARTICLE	IF	CITATIONS
145	A functional variant in <i>TP63</i> at 3q28 associated with bladder cancer risk by creating an miR-140 binding site. <i>International Journal of Cancer</i> , 2016, 139, 65-74.	2.3	27
146	Norcantharidin induces autophagy-related prostate cancer cell death through Beclin-1 upregulation by miR-129-5p suppression. <i>Tumor Biology</i> , 2016, 37, 15643-15648.	0.8	26
147	Increased expression of interleukin-8 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma. <i>Tumor Biology</i> , 2016, 37, 4523-4529.	0.8	11
148	ITGA2B and ITGA8 are predictive of prognosis in clear cell renal cell carcinoma patients. <i>Tumor Biology</i> , 2016, 37, 253-262.	0.8	34
149	Increased B4GALT1 expression associates with adverse outcome in patients with non-metastatic clear cell renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 32723-32730.	0.8	24
150	RECORD-4 phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Final OS analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 560-560.	0.8	0
151	Identification and validation of an 8-gene expression signature for predicting high-Fuhrman grade renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 526-526.	0.8	0
152	Sorafenib versus sunitinib as first-line treatment in metastatic renal cell carcinoma: Largest multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 594-594.	0.8	0
153	Chinese guidelines on the management of renal cell carcinoma (2015 edition). <i>Chinese Clinical Oncology</i> , 2016, 5, 12.	0.4	8
154	Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2015, 6, 222-230.	2.9	61
155	ADIPOQ polymorphism rs182052 is associated with clear cell renal cell carcinoma. <i>Cancer Science</i> , 2015, 106, 687-691.	1.7	18
156	Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer. <i>Scientific Reports</i> , 2015, 5, 7654.	1.6	140
157	Abnormal methylation status of FBXW10 and SMPD3, and associations with clinical characteristics in clear cell renal cell carcinoma. <i>Oncology Letters</i> , 2015, 10, 3073-3080.	0.8	36
158	Age-Dependent Association between Sex and Renal Cell Carcinoma Mortality: a Population-Based Analysis. <i>Scientific Reports</i> , 2015, 5, 9160.	1.6	32
159	Two novel <i>PRKCI</i> polymorphisms and prostate cancer risk in an Eastern Chinese Han population. <i>Molecular Carcinogenesis</i> , 2015, 54, 632-641.	1.3	4
160	Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study. <i>OncoTargets and Therapy</i> , 2015, 8, 1363.	1.0	14
161	Prognostic Value of Components of Body Composition in Patients Treated with Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Case Series. <i>PLoS ONE</i> , 2015, 10, e0118022.	1.1	32
162	Expression of Dicer and Its Related MiRNAs in the Progression of Prostate Cancer. <i>PLoS ONE</i> , 2015, 10, e0120159.	1.1	19

#	ARTICLE	IF	CITATIONS
163	Outcomes of patients with lymph node metastasis treated with radical prostatectomy and adjuvant androgen deprivation therapy in a Chinese population: results from a cohort study. <i>World Journal of Surgical Oncology</i> , 2015, 13, 172.	0.8	6
164	A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study. <i>Scientific Reports</i> , 2015, 5, 10905.	1.6	31
165	Retrograde radical cystectomy and consequent peritoneal cavity reconstruction benefits localized male bladder cancer: results from a cohort study. <i>World Journal of Surgical Oncology</i> , 2015, 13, 132.	0.8	5
166	Large-scale association analysis in Asians identifies new susceptibility loci for prostate cancer. <i>Nature Communications</i> , 2015, 6, 8469.	5.8	51
167	NADP <sup>+</sup> -IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance. <i>Molecular Cell</i> , 2015, 60, 661-675.	4.5	175
168	RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4518-4518.	0.8	5
169	Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy. <i>Oncotarget</i> , 2015, 6, 32212-32219.	0.8	23
170	Upregulation of COL6A1 is predictive of poor prognosis in clear cell renal cell carcinoma patients. <i>Oncotarget</i> , 2015, 6, 27378-27387.	0.8	26
171	A single nucleotide polymorphism in <i>ADIPOQ</i> predicts biochemical recurrence after radical prostatectomy in localized prostate cancer. <i>Oncotarget</i> , 2015, 6, 32205-32211.	0.8	18
172	Chinese guidelines on the management of renal cell carcinoma (2015 edition). <i>Annals of Translational Medicine</i> , 2015, 3, 279.	0.7	13
173	A randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with metastatic renal cell carcinoma (NCT02330783).. <i>Journal of Clinical Oncology</i> , 2015, 33, e15591-e15591.	0.8	0
174	CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 15708-15.	1.3	21
175	Clinical outcome of advanced and metastatic renal cell carcinoma treated with targeted therapy: is there a difference between young and old patients?. <i>OncoTargets and Therapy</i> , 2014, 7, 2043.	1.0	9
176	Targeting the Neddylaton Pathway to Suppress the Growth of Prostate Cancer Cells: Therapeutic Implication for the Men's Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	20
177	Complicated variation of simple renal cyst usually means malignancy: results from a cohort study. <i>World Journal of Surgical Oncology</i> , 2014, 12, 316.	0.8	8
178	Lower skeletal muscle index and early complications in patients undergoing radical cystectomy for bladder cancer. <i>World Journal of Surgical Oncology</i> , 2014, 12, 14.	0.8	47
179	Use of Targeted Therapies for Advanced Renal Cell Carcinoma in the Asia-Pacific Region: Opinion Statement From China, Japan, Taiwan, Korea, and Australia. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 225-233.	0.9	22
180	Correlation of blood eosinophil level with the clinical benefit of sorafenib in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15545-e15545.	0.8	0

#	ARTICLE	IF	CITATIONS
181	A multicenter, noncontrolled clinical study of sorafenib adjuvant therapy in advanced renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, e15553-e15553.	0.8	0
182	ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2014, 32, TPS4595-TPS4595.	0.8	1
183	Clinical significance of Tmprss4 in prostate cancer. International Journal of Clinical and Experimental Pathology, 2014, 7, 8053-8.	0.5	5
184	Genetic variants in telomere-maintenance genes and bladder cancer risk. Chinese-German Journal of Clinical Oncology, 2013, 12, 448-453.	0.1	0
185	Sorafenib treatment of Asian patients with advanced renal cell carcinoma (RCC) in daily practice: Subset analysis of the large non-interventional PREDICT study.. Journal of Clinical Oncology, 2012, 30, 4628-4628.	0.8	2
186	Axitinib versus sorafenib as secondâ€line therapy in Asian patients with metastatic renal cell carcinoma (mRCC): Results from a registrational study.. Journal of Clinical Oncology, 2012, 30, LBA4537-LBA4537.	0.8	1
187	Axitinib versus sorafenib as secondâ€line therapy in Asian patients with metastatic renal cell carcinoma (mRCC): Results from a registrational study.. Journal of Clinical Oncology, 2012, 30, LBA4537-LBA4537.	0.8	0